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associated with lower incidence of both symptomatic and severe hypoglycaemic events, 
resulting in an incremental beneﬁ t of 0.12 QALYs and an incremental cost-effectiveness 
ratio (ICER) of c13,931 per QALY gained. Modest reductions in all macro-vascular 
and micro-vascular complications were seen in those receiving saxagliptin + MET 
compared with SU + MET. Sensitivity analysis showed that treatment-related weight 
changes, as a risk factor for complications, represent the most inﬂ uential driver of cost-
effectiveness. CONCLUSIONS: Saxagliptin is associated with improved outcomes, a 
lower incidence of hypoglycaemic events, and weight neutrality, when compared with 
generic SU, at a cost that would likely be considered acceptable in the German setting.
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OBJECTIVES: Saxagliptin is indicated as an add-on combination therapy for adult 
patients with diabetes mellitus type 2 (T2D) to improve glycaemic control in combina-
tion with metformin, a sulphonylurea (SU) or a thiazolidinedione (TZD). The objective 
of this study was to evaluate the cost-effectiveness in Spain of saxagliptin when added 
to metformin in comparison with SU plus metformin or TZD plus metformin. 
METHODS: The analysis uses the Cardiff Long Term Model which simulates treatment 
pathways of pharmacological treatment of T2D from initiation of treatment until death. 
Efﬁ cacy and safety data are based on an indirect comparison of saxagliptin and SU and 
TZD based on the similarity in safety and efﬁ cacy between saxagliptin and sitagliptin 
demonstrated in a 18-week non-inferiority study (CV181,056). Available direct com-
parative trials between sitagliptin and TZDs and SUs are used to serve as data sources 
to assign efﬁ cacy and safety parameters. Spanish costs are used as for macro and micro-
vascular complications as well as adverse events such as severe hypoglycemia. Utility 
decrements for ischemic heart disease, myocardial infarction, congestive heart failure, 
stroke, blindness, end-stage renal disease, transplant, amputation and body mass index 
are also accounted in the model. Health outcomes are measured in terms of QALYs, 
assuming that the lifetime QALY is affected by complications, occurrence of hypogly-
caemic episodes and weight changes. The perspective used is that of the Spanish Health 
System. RESULTS: Saxagliptin as add on to metformin is cost-effective compared with 
SU and TZD (ICER < c10,000). Extensive univariate sensitivity analysis shows that the 
most inﬂ uential factor is the weight variation, which increases with treatment with SU 
and TZD whereas DPP-4 inhibitors have shown to be weight neutral. CONCLUSIONS: 
The cost-effectiveness analysis shows that saxagliptin is cost-effective compared with 
both SU and TZD in combination with metformin for the treatment of T2DM in Spain.
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OBJECTIVES: Although having substantial costs, the new antidiabetics for Type 2 
diabetes treatment present more alternatives for glycemic control of the disease. To 
evaluate their cost-effectiveness, the New Antidiabetics for Type 2 diabetes indexed 
on PubMed, EMBASE databases and American Diabetes Association abstracts were 
evaluated. METHODS: The cost-effectiveness of Type 2 diabetes based on the new 
antidiabetics was analyzed through literature review. Searches were carried out in 
PubMed, EMBASE and ADA abstracts to identify the articles published from 2008 
to 2010, keying in the terms “cost-effectiveness” and “type 2 diabetes” with language 
ﬁ ltering, “English.” The language ﬁ lter for “Turkish” was also used but no result was 
achieved. Upon this ﬁ ltration, the abstracts were reviewed to determine whether they 
included antidiabetics. RESULTS: Ten full texts, seven abstracts and three peer 
reviews were identiﬁ ed. In all studies, the cost-effectiveness of antidiabetics was 
assessed using the validated CORE Diabetes Model, except for two based on the 
Discrete Event Simulation Model. The outcomes from IMPROVE, PROactive, 
PRESENT, UKPDS and PREDICTIVE trials were used. In these studies, biphasic 
insulin aspart, exenatide, pioglitazone, insulin detemir, insulin glargine and sitagliptin 
were all studied under different settings and against various comparators. Biphasic 
insulin aspart versus human premix insulin was mostly found to be cost-effective in 
certain studies. Exenatide versus insulin glargine was established to be likely cost-
effective in two studies. Pioglitazone was found to be dominant compared to rosigli-
tazone. Insulin detemir was established to be cost-saving in comparison with OAD or 
NPH insulin, or insulin glargine. Sitagliptin was regarded as either cost-effective or 
cost-saving compared to rosiglitazone. CONCLUSIONS: Different results in terms of 
cost-effectiveness of various antidiabetics under certain settings and against varied 
comparators were achieved. In future, demonstrated gains in QALYs will be found to 
be essential for these antidiabetics to be regarded as cost-effective.
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OBJECTIVES: Continuous glucose monitoring (CGM) has been found to improve 
glycemic control in type 1 diabetes in recent trials. The objective of this study is to 
assess the cost-effectiveness of CGM compared with self-monitoring of blood glucose 
(SMBG) in type 1 diabetes patients, from a societal perspective in the The Netherlands. 
METHODS: The analysis was performed using the CORE Diabetes model with inputs 
for the The Netherlands. Clinical effectiveness of CGM in terms of lowering HbA1c 
was taken from the GuardControl study. Costs of complications and complication-
related days off work were based on data from Erasmus University Rotterdam. Annual 
treatment costs were estimated using cost information from the Healthcare Insurance 
Board. Costs and effects were discounted at 4% and 1.5%, respectively. a lifetime 
horizon (60 years) was adopted for the analysis. a range of sensitivity analyses were 
conducted. RESULTS: The total costs per patient over 60 years for the CGM arm 
were c10,069 (73,348) higher than costs for the SMBG arm. Complication costs were 
lower, and treatment costs were higher for the CGM compared to the SMBG arm. 
Compared to the SMBG arm, 0.463 (3.063) QALYs were gained in the CGM group. 
The cost per QALY gained was c21,731. Probabilistic sensitivity analyses showed that 
this result is robust. CONCLUSIONS: At a willingness to pay threshold of c40,000 
per QALY, CGM appears to be a cost-effective treatment option compared to SMBG 
in patients with type 1 diabetes.
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OBJECTIVES: A multifaceted quality improvement programme for the care of diabe-
tes was implemented in two different Flemish regions (Aalst and Leuven) and with 
slightly different modalities. The overall objective of the programmes was to improve 
adherence to evidence-based guidelines on diabetes in primary care physicians. The 
aim of this study was to assess the cost-effectiveness of the programs compared to 
regular care in both regions. METHODS: Short-term effects of the programmes were 
extrapolated to long-term hard endpoints, using the validated UKPDS Outcomes 
Model, supplemented by two self-developed Markov models to account for beneﬁ ts 
on process parameters (screening for retinopathy and nephropathy). a simulation of 
the evolution of patients was made over a time horizon of 25 years with cycles of 1 
year, from a public health care payer perspective. Cost data of the different disease 
states and extra direct medical costs due to intensiﬁ ed patient management were col-
lected from literature and from the National Institute for Health and Disability Insur-
ance. For the self developed Markov models, utility data for all states were obtained 
from published studies and transition probabilities were obtained from local epide-
miological studies and published trials. In the simulation, the intervention was 
assumed to be implemented three times over the predicted life expectancy. Determin-
istic sensitivity analyses were performed on the combined results of outcome and 
process parameters. RESULTS: At a cost of intervention of c185 (Aalst) and c284 
(Leuven) per patient, the analyses show ICER’S for Aalst and Leuven of respectively 
c15,206.70/QALY and c10,397.96/QALY. Sensitivity analyses show few inﬂ uence of 
changed input variables. CONCLUSIONS: When using a ratio of c30,000/QALY as 
threshold of willingness to pay for health gain, the diabetes health care programmes 
have an acceptable ICER in both regions.
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OBJECTIVES: To analyze the effectiveness and safety of three treatment regimens, 
and to project and compare long-term outcomes and costs of complications of type 2 
diabetes mellitus (T2DM). METHODS: Data of 3678 patients (mean age 49.6 ± 0.19 
years; 47% men; mean diabetes’s duration—6 years) included in “evaluation of dia-
betes mellitus complications” program were taken for mathematic simulation using 
the validated Center for Outcomes Research (CORE) Diabetes Model. Patients were 
randomly divided into three groups: insulin therapy (NovoMix® 30), oral antidiabetic 
drugs (OAD; combination of glibenclamide + metformin in most cases) and diet. Life 
expectancy, cumulative incidence of cardiovascular, ocular events and health care 
costs were estimated over period duration—50 years. RESULTS: Estimated life expec-
tancy was higher in insulin group compared with OAD and diet groups (17.2, 16.5, 
and 16.0 years). The best QALY’s results were also achieved in insulin group (10.7, 
10.2 and 9.9 years) due to decreased rates of myocardial infarction (morbidity/mortal-
ity), decompensated heart failure, ocular complications and diabetic retinopathy. 
Higher direct costs for years of life gained in insulin group (1287, 1203, and 1180 
thousands of rub.) were associated with concomitant decreasing of indirect costs 
(362.7, 382.5, and 381.3 thousands of rub.). The costs for one patient with T2DM 
per 1 year were nearly the same in three groups (95.9, 95.9, and 97.6 thousands of 
rub.). CONCLUSIONS: use of the CORE Diabetes Model life expectancy, diabetes 
complications, and costs favored insulin NovoMix® 30 therapies compared with 
OAD or diet in treatment of T2DM.
